Literature DB >> 3791555

Schedule-dependent antitumor and toxic effects of thymidine and 5-fluorouracil in AKR and L1210 leukemias.

G Santelli, F Valeriote.   

Abstract

The effect of thymidine (dThd) on 5-fluorouracil (FUra) toxicity to both leukemia stem cells (LCFU) and hematopoietic stem cells (NCFU) was examined. A dose of 10 mg/mouse of dThd given within 1 h before FUra enhanced FUra cytotoxicity to NCFU by a factor of about 4. This effect was also reflected in the reduction of the LD10. The dose-survival curve of FUra in AKR leukemia was modified by the prior administration of dThd 10 mg/mouse: the cytotoxic effect of FUra was enhanced by a factor of between 100 and 1000 throughout the dose range studied. These findings were reflected in the ILS studies. When given by 'high dose' infusion dThd had only a slight antitumor effect on AKR leukemia, and no effect on L1210. When large doses of dThd were infused concomitantly with FUra they potentiated its cytotoxicity against NCFU, AKR LCFU, and L1210 LCFU in a dose-dependent manner and by a maximum factor of about 70.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3791555     DOI: 10.1007/bf00262276

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  21 in total

1.  DISSEMINATION AND GROWTH OF TRANSPLANTED ISOLOGOUS MURINE LYMPHOMA CELLS.

Authors:  W R BRUCE; B E MEEKER
Journal:  J Natl Cancer Inst       Date:  1964-05       Impact factor: 13.506

2.  A direct measurement of the radiation sensitivity of normal mouse bone marrow cells.

Authors:  J E TILL; E A McCULLOCH
Journal:  Radiat Res       Date:  1961-02       Impact factor: 2.841

3.  Kinetics of the lethal effect of actinomycin D on normal and leukemic cells.

Authors:  F Valeriote; T Vietti; S Tolen
Journal:  Cancer Res       Date:  1973-11       Impact factor: 12.701

4.  Phase I evaluation and pharmacokinetic study of weekly iv thymidine and 5-FU in patients with advanced colorectal carcinoma.

Authors:  G Lynch; N Kemeny; H Chun; D Martin; C Young
Journal:  Cancer Treat Rep       Date:  1985-02

5.  Thymidine and 5-FU: a Phase II pilot study in colorectal and breast carcinomas.

Authors:  C A Presant; P Multhauf; L Klein; C Chan; F F Chang; G Hum; R Joseph; R Opfell; S Lemkin; T Shiftan; D Plotkin
Journal:  Cancer Treat Rep       Date:  1983 Jul-Aug

6.  Potentiation of the anti-tumor activity of 5FU by thymidine and its correlation with the formation of (5FU)RNA.

Authors:  S Spiegelman; R Nayak; R Sawyer; R Stolfi; D Martin
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

7.  Kinetics of cytotoxicity of VM-26 and VP-16-213 on L1210 leukemia and hematopoietic stem cells.

Authors:  T J Vietti; F A Valeriote; R Kalish; D Coulter
Journal:  Cancer Treat Rep       Date:  1978-09

8.  Activity of thymidine as a chemotherapeutic agent against human tumor xenografts in nude mice.

Authors:  S B Howell; R S Jenkins; J Streifel
Journal:  Cancer Res       Date:  1979-10       Impact factor: 12.701

9.  Cellular quantitation of in vivo effects of 1-beta-D-arabinofuranosylcytosine on leukemia L1210.

Authors:  M Edelstein; F Valeriote; T Vietti
Journal:  J Natl Cancer Inst       Date:  1977-04       Impact factor: 13.506

10.  Studies of the dissemination and quantitative transplantation of a lymphocytic leukaemia of CBA mice.

Authors:  H B HEWITT
Journal:  Br J Cancer       Date:  1958-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.